UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
current report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether either registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if either registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Director
On August 2, 2023, Bryan C. Cressey, a director of the Select Medical Holdings Corporation (the “Company”) and chairman of the Compensation Committee (the “Compensation Committee”) of the Company’s Board of Directors, notified the Company of his decision to resign as a director, effective August 2, 2023. Mr. Cressey’s resignation was not the result of any disagreement with the Company or any of its officers or other directors on any matter relating to the operations, policies or practices of the Company.
Compensatory Arrangements of Executive Officers
On August 1, 2023, the Compensation Committee awarded restricted shares of the Company’s common stock to certain of the named executive officers pursuant to the Company’s 2020 Equity Incentive Plan. The shares awarded to Messrs. Chernow, Robert Ortenzio, Rocco Ortenzio, Jackson and Tarvin will vest equally on each of the first three anniversaries of the date of grant. The shares awarded to Messrs. Saich and Mullin will vest in full on August 1, 2026. The grant of restricted stock to each named executive officer is listed below.
| Name of Executive | Shares of Restricted Stock Granted | |||
| David S. Chernow | 250,000 | |||
| Robert A. Ortenzio | 250,000 | |||
| Rocco A. Ortenzio | 150,000 | |||
| Martin F. Jackson | 150,000 | |||
| Michael E. Tarvin | 100,000 | |||
| John A. Saich | 75,000 | |||
| Thomas P. Mullin | 75,000 | |||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.
| SELECT MEDICAL HOLDINGS CORPORATION | ||
| Date: August 2, 2023 | By: | /s/ Michael E. Tarvin |
| Michael E. Tarvin | ||
| Executive Vice President, General Counsel and Secretary | ||